Introduction
Muscle wasting (MW) in catabolic conditions (e.g. burn injury, BI) is a major risk factor affecting prognosis. Activation of IL-1β/NF-κB, IL-6/STAT3 and/or FoxO-mediated gene transcription pathways is the pivotal trigger of inflammatory response-induced protein catabolic processes in muscle. The α7 acetylcholine receptors (α7AChRs) are up-regulated in macrophages and peripheral tissues including skeletal muscle during MW conditions. Stimulation of α7AChRs mitigates inflammatory responses. Hypothesis tested is that attenuation of inflammation by α7AChRs stimulation with specific α7AChRs agonist, GTS-21, will reverse BI-induced body mass and MW by modulating inflammatory and proteolytic signals.
Methods
Body surface area (30%) BI or Sham BI mice were treated with GTS-21 or saline. Tibialis anterior (TA) muscle was harvested at 6 hours (6h), day 1 or 3 to examine inflammatory and proteolytic signals.
Results
GTS-21 significantly ameliorated the BI-induced increased expression of inflammatory cytokines IL-6, IL-1β, CXCL2 (6h), phosphorylated STAT3 and NF-κB (Day1) in TA muscle. GTS-21 also significantly inhibited BI-induced increase of MuRF1 and FOXO1 (Day1). Consistent with the cytokine and inflammatory mediator changes, BI-induced body weight and TA muscle mass loss at Day3 were mitigated by GTS-21 treatment. The beneficial effect of GTS-21 on BI changes were absent in methyllycaconitine (α7AChR antagonist) treated WT and α7AChR knock out mice.
Conclusion
GTS-21 stimulation of α7AChRs, by modulating multiple molecular signals related to inflammation and proteolysis, attenuates protein wasting, evidenced by maintenance of body weight and attenuation of distant muscle mass loss after BI. GTS-21 can be a novel, potent therapeutic option for reversal of BI-induced MW.